PEDIATRIC OSTEOSARCOMA - TREATMENT OF THE PRIMARY TUMOR WITH INTRAVENOUS CIS-DIAMMINEDICHLOROPLATINUM-II (CDP) - COMPARISON OF THE RESULTS WITH THE REPORTED EFFICACY OF INTRAARTERIAL CDP

Intravenous cis-Diamminedichloroplatinum-II (CDP) was administered to 10 patients with osteosarcoma to treat the primary tumor in 8 and bone metastases in 2. Three patients also had pulmonary metastases. The in tent was to deliver 7 courses (150 mg/M2 q 2 weeks) over 3 months (tot al cumulative dose 1050/mg/M2). However, this was only accomplished in 2 patients; in the remaining 8 the full course was not administered b ecause of temporary renal insufficiency (3), tumor escape (1) and appa rent response after 4-6 courses suggesting that no further benefit wou ld accrue (4). Overall, clinical and/or radiologic responses were obse rved in 9 patients. In 6 of 9 tumors subjected to surgical resection ( 66%), necrosis in excess of 65% was observed. Optimum results were ach ieved with a cumulative dose of 600 mg/M2 administered over 6 weeks. T hese results suggest that intravenous CDP may be as efficacious as int ra-arterial CDP which has produced similar responses.